Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

1. Non-hormonal-based treatments for menopausal symptoms

Non-hormonal-based treatments for menopausal symptoms Non-hormonal-based treatments for menopausal symptoms | British Menopause Society Search for: Summary consensus statement Non-hormonal-based treatments for menopausal symptoms Non-hormonal-based treatments for menopausal symptoms 2018-04-13T10:06:04+01:00 Summary practice points As clinicians we must be familiar with alternative therapies, to help inform and guide women as to which options are most likely to be beneficial to them. Few (...) complementary and alternative treatment options have proven evidence of effectiveness, but although many options do not stand up to scrutiny from a robust and evidence based perspective there will be individual women who will benefit from some of these treatments. Placebo effect is not inconsiderable and in menopausal studies will play a part in individual experience and reported benefits The full statement, scientific papers, charts, presentations etc are available in the . If you are not a member you can

2020 British Menopause Society

2. Tibolone (Tibella) - for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause

Tibolone (Tibella) - for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization

2020 Health Canada - Drug and Health Product Register

3. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. (Abstract)

Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. Recent guidelines endorse using history of menopause before age 40 years to refine atherosclerotic cardiovascular disease risk assessments among middle-aged women. Robust data on cardiovascular disease risk in this population are lacking.To examine the development of cardiovascular diseases and cardiovascular risk factors in women with natural and surgical menopause before age 40 years.Cohort study (UK (...) Biobank), with adult residents of the United Kingdom recruited between 2006 and 2010. Of women who were 40 to 69 years old and postmenopausal at study enrollment, 144 260 were eligible for inclusion. Follow-up occurred through August 2016.Natural premature menopause (menopause before age 40 without oophorectomy) and surgical premature menopause (bilateral oophorectomy before age 40). Postmenopausal women without premature menopause served as the reference group.The primary outcome was a composite

2019 JAMA

4. Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. (Abstract)

Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. Whether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown.To examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups.Subgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT00000611).40 U.S

2019 Annals of Internal Medicine

5. Testosterone replacement in menopause

Testosterone replacement in menopause BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 4 1 How much and where does it come from? Testosterone is an important female hormone. Healthy young women produce approximately 100 – 400 mcg per day. This represents three to four times the amount of estrogen produced by the ovaries. Approximately half of endogenous testosterone and precursors are derived from the ovaries e.g. androstenedione and half (...) from the adrenal glands e.g. dehydroepiandrosterone. Some of the effects are direct and some due to peripheral conversion to estrogen by aromatase. Testosterone levels naturally decline throughout a woman’s lifespan. Loss of testosterone is particularly profound after iatrogenic i.e. surgical and medical menopause and premature ovarian insufficiency when testosterone production decreases by more than 50%. 2 What is its role in women? Testosterone contributes to libido, sexual arousal and orgasm

2019 British Menopause Society

6. Menopause and the Workplace Guidance: what to consider

Menopause and the Workplace Guidance: what to consider BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 3 Menopause and the workplace guidance: what to consider This factsheet provides a ‘how-to’ guide for employers and relevant staff within organisations that are considering writing their own guidance on the menopause. Introduction • In 2019, there are over 4.3million employed women in the UK aged 45-60. 1 • Given the average age (...) of a women’s menopause is 51 years 2 , a significant number of employed women will be working through their menopausal transition. • The experiences of the menopausal transition varies enormously between women. Some women will have no symptoms but most women will experience at least one symptom. 2 Up to a third of women will experience severe menopausal symptoms that can impact on their quality of life. 3,4 • It is the work context that women report greater difficulty in managing symptoms 5,6 and can feel

2019 British Menopause Society

7. British Menopause Society update on HRT supply shortages

British Menopause Society update on HRT supply shortages British Menopause Society further update on HRT supply shortages | British Menopause Society Search for: News 2019-08-23T12:14:14+01:00 23 August 2019 | In response to the ongoing HRT shortages, the British Menopause Society has produced this further update on the current availability of HRT products. This provides guidance to BMS members and clinical practitioners who may be experiencing difficulties with HRT supplies. There continues (...) . Available. Zumenon® 1mg oestradiol and 2mg oestradiol. Shortage of supplies. Elleste Solo™ MX patches 40mcg transdermal oestradiol. Available. Elleste Solo™ MX patches 80mcg transdermal oestradiol. Available. Mylan’s manufacturing partner continues to experience interruptions in the production of certain strengths of Elleste™, their Hormone Replacement Therapy (HRT). They have informed us that they will continue to provide updates on timing for resolution, as they receive them; to the British Menopause

2019 Royal College of Obstetricians and Gynaecologists

8. Are vaginal estradiol tablets (Vagifem) effective for genitourinary syndrome of menopause?

Are vaginal estradiol tablets (Vagifem) effective for genitourinary syndrome of menopause? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca June 10, 2019 Verifying the value of vaginal estradiol tablets Clinical Question: Are vaginal estradiol tablets (Vagifem®) effective for genitourinary syndrome of menopause? Bottom Line: Vaginal estradiol tablets are likely no better than placebo vaginal gel for reducing “most bothersome symptom scores” (mainly dyspareunia). However, compared to placebo vaginal tablets, they reduce symptoms (example: treatment “success” at 12 months in 86% versus 41% placebo). A non-medicated

2019 Tools for Practice

9. Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial (Abstract)

Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial We evaluated the effect of Internet-based cognitive behavioral therapy (iCBT), with or without therapist support, on the perceived impact of hot flushes and night sweats (HF/NS) and overall levels of menopausal symptoms (primary outcomes), sleep quality, HF/NS frequency, sexual functioning, psychological distress, and health (...) -related quality of life in breast cancer survivors with treatment-induced menopausal symptoms.We randomly assigned 254 breast cancer survivors to a therapist-guided or a self-managed iCBT group or to a waiting list control group. The 6-week iCBT program included psycho-education, behavior monitoring, and cognitive restructuring. Questionnaires were administered at baseline and at 10 weeks and 24 weeks postrandomization. We used mixed-effects models to compare the intervention groups with the control

2019 EvidenceUpdates

10. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health CONSENSUS RECOMMENDATIONS Managementofgenitourinarysyndromeofmenopauseinwomenwith orathighriskforbreastcancer:consensusrecommendationsfromThe North American Menopause Society and The International Society for the Study of Women’s Sexual Health Stephanie S (...) , CCD, NCMP, IF, FACOG, 14 Shari B. Goldfarb, MD, 15 and Sheryl A. Kingsberg, PhD 16 Abstract TheobjectiveofTheNorthAmericanMenopauseSociety(NAMS)andTheInternationalSocietyfortheStudyof Women’s Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendationswillassisthealthcareprovidersinmanagingGSMwithagoalofimprovingthecareandqualityof life

2019 The North American Menopause Society

11. Menopause

Menopause Menopause - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Menopause Last reviewed: February 2019 Last updated: February 2019 Summary The diagnosis is clinical, based on the absence of menses for 12 months, and does not require further testing for appropriately presenting patients. Oestrogen therapy is an effective treatment for the management of menopausal symptoms including hot flushes, night sweats (...) , and is unlikely to increase the risk of stroke or venous thrombosis above that of non-users. Non-hormonal interventions may help women who have a contraindication to, or cannot tolerate, HT. However, they are less effective than HT in controlling menopausal symptoms. Definition Onset of the menopause is heralded by the cessation of menses for at least 12 consecutive months, without some other reason for amenorrhoea (such as pregnancy, hormone therapy, or other medical condition). No further testing

2019 BMJ Best Practice

12. Effects of acute dietary nitrate supplementation on aortic blood pressures and pulse wave characteristics in post-menopausal women. (Abstract)

Effects of acute dietary nitrate supplementation on aortic blood pressures and pulse wave characteristics in post-menopausal women. Consumption of nitrate-rich beetroot juice can lower blood pressure in peripheral as well as central arteries and may exert additional hemodynamic benefits (e.g. reduced aortic wave reflections). The specific influence of nitrate supplementation on arterial pressures and aortic wave properties in postmenopausal women, a group that experiences accelerated increases (...) ± 1 yr) before and 100 min after consumption of 140 ml of either nitrate-rich (9.7 mmol, 0.6 gm NO3-) or nitrate-depleted beetroot juice on randomized visits approximately 10 days apart (cross-over design). Ten young premenopausal women (22 ± 1 yr) served as a reference (non-supplemented) cohort.Brachial and derived-aortic variables showed the expected age-associated differences in these women (all p < 0.05). In post-menopausal women, nitrate supplementation reduced (p < 0.05 vs. placebo visit

2019 Nitric oxide : biology and chemistry

13. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial Full Text available with Trip Pro

Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial To assess the short- and long-term effects of mindfulness-based stress reduction (MBSR) on the resulting quality of life, sexual functioning, and sexual distress after risk-reducing salpingo-oophorectomy (RRSO).Randomised controlled trial.A specialised family cancer clinic of the university medical center Groningen.Sixty-six women carriers (...) of the BRCA1/2 mutation who developed at least two moderate-to-severe menopausal symptoms after RRSO.Women were randomised to an 8-week MBSR training programme or to care as usual (CAU).Change in the Menopause-Specific Quality of Life Questionnaire (MENQOL), the Female Sexual Function Index, and the Female Sexual Distress Scale, administered from baseline at 3, 6, and 12 months. Linear mixed modelling was applied to compare the effect of MBSR with CAU over time.At 3 and 12 months, there were statistically

2018 EvidenceUpdates

14. Acupuncture for symptoms in menopause transition: a randomized controlled trial (Abstract)

Acupuncture for symptoms in menopause transition: a randomized controlled trial Acupuncture has been used for women during menopause transition, but evidence is limited.We sought to evaluate the efficacy of electroacupuncture on relieving symptoms of women during menopause transition.We conducted a prospective, multicenter, randomized, participant-blinded trial in China mainland. Subjects were randomized to receive 24 treatment sessions of electroacupuncture at traditional acupoints or sham (...) electroacupuncture at nonacupoints over 8 weeks with 24 weeks' follow-up. Primary outcome was the change from baseline in the total score of Menopause Rating Scale at week 8. Secondary outcomes included the changes from baseline in the average 24-hour hot flash score, the Menopause Rating Scale subscale scores, the total score of Menopause-Specific Quality of Life Questionnaire and its subscales, and serum female hormones. All analyses were performed with a 2-sided P value of < .05 considered significant based

2018 EvidenceUpdates

15. Menopause

Menopause Top results for menopause - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for menopause The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

16. Menopause

Menopause Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

17. [Gender Features of Radical Oxidation of Lipids in Menopausal Women and Men in Andropause]. Full Text available with Trip Pro

[Gender Features of Radical Oxidation of Lipids in Menopausal Women and Men in Andropause]. Our aim was to assess lipid peroxidation ― antioxidant protection in menopausal women and men in andropause and to compare these processes in different gender and age groups.74 women and 37 men were examined. This study was a prospective, randomized cohort study. Women were divided into perimenopausal group (n=22, mean age 49.03±3.13), postmenopausal group (n=15, mean age 54.43±4.54) and control (n=37 (...) by 43% (p<0,05), α-tocopherol by 24% (p<0.05), SOD activity by 9% (p<0.05).Coefficient oxidative stress in perimenopausal women was 2,5, in postmenopausal ― 3,48, in andropause ― 0,97.Expressed lipid peroxidation activity is more physiological in andropause than in menopause. Men in andropause have large functional reserves and adaptive capacity than menopausal women.

2018 Vestnik Rossiiskoi akademii meditsinskikh nauk Controlled trial quality: uncertain

18. Should This Patient Receive Hormone Therapy for Her Menopausal Symptoms?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

Should This Patient Receive Hormone Therapy for Her Menopausal Symptoms?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Hormone therapy (HT) was widely prescribed in the 1980s and 1990s and has been controversial since the initial results of the Women's Health Initiative (WHI) trial in the early 2000s suggested that it increased risk for breast cancer and coronary heart disease and did not prolong life. However, more recent data and reexamination of the WHI results suggest (...) that HT is safe and effective for many women when used around the time of menopause. Two experts debate the 2017 Hormone Therapy Position Statement of The North American Menopause Society, which recommends HT as first-line treatment of vasomotor symptoms, and apply it to the care of Ms. R, a 52-year-old woman with severe hot flashes, sleep disturbance, and irritability.

2018 Annals of Internal Medicine

19. HIV and the menopause

HIV and the menopause BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 2 HIV and the menopause Introduction Over the past two decades, antiretroviral therapy (ART) has transformed HIV into a long-term condition with normal life expectancy for people stable on treatment. In 2016, 10,350 women living with HIV aged 45-56 (the age when women usually go through the menopause) attended HIV clinics in the UK. This is nearly half of all women (...) attending for HIV care in the UK, and is five times the number in 2006 1 . As the number of women living with HIV reaching their midlife grows, we are beginning to understand the importance of addressing their healthcare needs during the menopause. What is the impact of the menopause on women living with HIV? • The menopause transition can have multi-dimensional impacts on the health and well-being of women living with HIV. • There is conflicting evidence on the association between HIV and earlier age

2018 British Menopause Society

20. The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer | British Menopause Society Search for: Summary consensus statement The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer The diagnosis of the menopause and management (...) of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer 2018-12-05T16:45:20+01:00 Key points An early menopause, estrogen deficiency symptoms and arthralgia are common side effects of systemic breast cancer therapies. Symptoms may persist for the duration of treatment and in some cases continue after treatment completion. The NICE Menopause Guidance [NG23] recommends referral of women to a healthcare professional with expertise in gynaecological endocrinology for counselling about

2018 British Menopause Society